Replimune Group (NASDAQ:REPL) Trading 6.7% Higher – Here’s What Happened

Shares of Replimune Group, Inc. (NASDAQ:REPL) traded up 6.7% during trading on Monday . The company traded as high as $8.16 and last traded at $8.53. 41,152 shares were traded during trading, a decline of 95% from the average session volume of 863,411 shares. The stock had previously closed at $8.00.

Analyst Upgrades and Downgrades

REPL has been the topic of a number of research reports. JPMorgan Chase & Co. raised their price objective on Replimune Group from $16.00 to $18.00 and gave the stock an “overweight” rating in a report on Wednesday, February 26th. BMO Capital Markets increased their price target on Replimune Group from $18.00 to $27.00 and gave the company an “outperform” rating in a report on Wednesday, January 22nd. Finally, HC Wainwright raised their price objective on Replimune Group from $21.00 to $22.00 and gave the company a “buy” rating in a research report on Thursday, February 13th. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Replimune Group presently has a consensus rating of “Buy” and an average target price of $19.43.

Replimune Group Stock Performance

The company has a debt-to-equity ratio of 0.14, a quick ratio of 11.43 and a current ratio of 11.43. The company has a 50 day moving average price of $10.54 and a 200 day moving average price of $11.71. The company has a market capitalization of $670.80 million, a PE ratio of -2.84 and a beta of 1.26.

Replimune Group (NASDAQ:REPL) last announced its quarterly earnings data on Wednesday, February 12th. The company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.70) by ($0.09). Equities analysts forecast that Replimune Group, Inc. will post -2.97 EPS for the current year.

Institutional Trading of Replimune Group

Institutional investors and hedge funds have recently bought and sold shares of the company. Geode Capital Management LLC increased its holdings in shares of Replimune Group by 17.9% in the 3rd quarter. Geode Capital Management LLC now owns 1,428,301 shares of the company’s stock valued at $15,657,000 after acquiring an additional 217,308 shares during the last quarter. Barclays PLC increased its stake in Replimune Group by 165.5% during the third quarter. Barclays PLC now owns 158,491 shares of the company’s stock valued at $1,738,000 after purchasing an additional 98,791 shares during the last quarter. Victory Capital Management Inc. bought a new stake in Replimune Group during the fourth quarter valued at $543,000. Swiss National Bank raised its holdings in shares of Replimune Group by 57.4% during the fourth quarter. Swiss National Bank now owns 103,700 shares of the company’s stock worth $1,256,000 after purchasing an additional 37,800 shares during the period. Finally, Bank of New York Mellon Corp lifted its position in shares of Replimune Group by 7.3% in the 4th quarter. Bank of New York Mellon Corp now owns 174,518 shares of the company’s stock worth $2,113,000 after buying an additional 11,893 shares during the last quarter. Institutional investors and hedge funds own 92.53% of the company’s stock.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.